Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002418 · ClinicalTrials.gov registry record · Phase 2
The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
NCT00002418: Clinical Trial Phase 2 study, sponsored by Bristol-Myers Squibb.
NCT00002418 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 25 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00002418, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
Study Summary
The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to respond to protease inhibitors (PIs). The drug combination will contain didanosine (ddI) plus stavudine (d4T) plus nevirapine (NVP) plus MKC-442. Hydroxyurea (HU) may be added.
Interventions
- DRUG Hydroxyurea
- DRUG Stavudine
- DRUG Didanosine
- DRUG Nevirapine
- DRUG Emivirine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Phase | Phase 2 |
Why NCT00002418 stopped before completion
NCT00002418 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (81% lower).
The record links to 0 conditions, and to 5 interventions - of which Hydroxyurea is the first listed.
NCT00002418 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00002418 about?
NCT00002418 is a clinical study titled "The Safety and Effectiveness of Didanosine Plus Stavudine Plus Nevirapine Combined With MKC-442 in HIV-Infected Patients Who Have Not Had Success With Protease Inhibitors". The purpose of this study is to see if it is safe and effective to give a new anti-HIV drug combination to HIV-infected patients who have never taken nonnucleoside reverse transcriptase inhibitors (NNRTIs) and who have failed to respond to protease inhibitors (PIs). The drug combination will contain...
What is the current status of trial NCT00002418?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 25 participants.
What interventions are being tested in trial NCT00002418?
The interventions under investigation include: Hydroxyurea (DRUG), Stavudine (DRUG), Didanosine (DRUG), Nevirapine (DRUG), Emivirine (DRUG).
Who is sponsoring clinical trial NCT00002418?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00002418's enrollment target sits among peer trials
25 1719th of 2000 higher than 245 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer